U.S. Gas Utilities Stock News

Royalty Pharma (RPRX) opened 2026 with Q1 revenue of US$631 million and basic EPS of US$0.69, alongside trailing twelve month revenue of about US$2.4 billion and EPS of US$1.93 that sit against a net profit margin of 33.9%. Over recent quarters the company has seen revenue move from US$568 million in Q1 2025 to US$631 million in Q1 2026, while quarterly EPS has ranged between US$0.07 and US$0.69. This sets up a results snapshot where forecast revenue and earnings growth meet a thinner margin...

Atlas Energy Solutions (AESI) opened Q1 2026 with revenue of US$265.6 million and a basic EPS loss of US$0.38, as net income excluding extra items came in at a loss of US$47.3 million. The company has seen quarterly revenue move from US$297.6 million in Q1 2025 to US$265.6 million in Q1 2026, while basic EPS shifted from a profit of US$0.01 to a loss of US$0.38 over the same period. This sets up a mixed read on top line scale versus bottom line pressure. For investors, the story in this print...

BlackLine (NasdaqGS:BL) opened Q1 2026 with revenue of US$183.2 million and basic EPS of US$0.14, setting a clear marker for how its profitability story is evolving. The company reported revenue of US$169.5 million in Q4 2024 and US$183.2 million in Q1 2026, while quarterly basic EPS has ranged from US$0.08 to US$0.90 over that period, giving investors a detailed look at how margins are being earned rather than assumed. See our full analysis for BlackLine. With the headline figures on the...

Elanco Animal Health (ELAN) opened 2026 with Q1 revenue of about US$1.4b and basic EPS of US$0.11, alongside net income of US$57m, setting a cleaner profit picture against a still loss-making trailing twelve months. Over that period, basic EPS stands at a US$0.49 loss on revenue of US$4.9b and a net loss of US$242m. Over recent quarters the company has seen quarterly revenue move from US$1.02b in Q4 2024 to US$1.19b in Q1 2025 and then to US$1.37b in Q1 2026. Quarterly basic EPS shifted from...

Chemours (CC) has kicked off Q1 2026 with revenue of US$1.4 billion, a basic EPS loss of US$0.19 and net income excluding extra items of a US$29 million loss, with trailing 12 month figures showing revenue of US$5.8 billion and a net loss of US$410 million or basic EPS of US$2.79. Over recent quarters the company has seen revenue move from US$1.37 billion in Q1 2025 to US$1.38 billion in Q4 2025 and now US$1.4 billion, while quarterly basic EPS has ranged from a loss of US$2.54 in Q2 2025 to...

Holley Q1 2026 headline results Holley (HLLY) opened 2026 with Q1 revenue of US$147.3 million and basic EPS of US$0.06, alongside net income of US$7.3 million, putting fresh quarterly profits in focus for investors watching the stock around US$2.87. The company has seen quarterly revenue move from US$153.0 million and EPS of US$0.02 in Q1 2025 to US$147.3 million and EPS of US$0.06 in Q1 2026. Meanwhile, trailing 12 month EPS shifted from a loss of US$0.20 in Q1 2025 to a profit of US$0.20 in...

Andersons (ANDE) opened 2026 with Q1 revenue of US$2.6b and basic EPS of US$0.98, alongside net income of US$33.2m. Over the trailing twelve months it has produced revenue of US$11.0b, basic EPS of US$3.78 and net income of US$128.6m. The company has seen quarterly revenue move between US$2.5b and US$3.1b and basic EPS range from roughly US$0.01 to US$1.98 over the past year. This performance feeds into a trailing net margin of 1.2%, which puts the focus on how efficiently each dollar of...

Neurocrine Biosciences (NBIX) opened 2026 with Q1 revenue of US$814.5 million and basic EPS of US$1.97, while trailing 12 month figures sit at US$3.1 billion of revenue and EPS of US$6.71, setting a firm earnings-season backdrop. The company has seen quarterly revenue move from US$572.6 million in Q1 2025 to US$814.5 million in Q1 2026, with basic EPS shifting from US$0.08 to US$1.97 over the same period. Earnings growth of 118.6% over the past year and forecast EPS growth of about 21.1% per...

Oncolytics Biotech reported new durability and response data for its pelareorep therapy in RAS-mutant MSS metastatic colorectal cancer. The pelareorep-based regimen outperformed historical benchmarks in second-line treatment, with longer median duration of response and higher objective response rates. The company has initiated enrollment in a Phase 2 randomized study and is in active discussions with the FDA on a potential accelerated approval pathway. For investors watching NasdaqCM:ONCY,...

Aurora Innovation (NasdaqGS:AUR) has signed its first commercial contract for fully driverless long haul trucking with McLane Company. The partnership will use autonomous trucks to run driverless routes in Texas for a major national distributor. Aurora plans to scale to 200 fully driverless trucks and broaden its US route network by year end. Aurora Innovation focuses on autonomous driving technology, with trucking as a key commercial application. The McLane agreement moves the company from...

Limbach Holdings (LMB) has kicked off Q1 2026 with revenue of US$138.9 million and basic EPS of US$0.37, alongside trailing 12 month EPS of US$2.85 on revenue of US$652.6 million. This helps frame the latest quarter against a broader earnings base. Over recent quarters the company has seen revenue move from US$133.1 million in Q1 2025 to a peak of US$186.9 million in Q4 2025, while basic EPS ranged from US$0.67 to US$1.06 over that stretch. This provides a clearer view of how the top line has...

Johnson Controls International (JCI) has just posted Q2 2026 results with revenue of US$6.1b and basic EPS of US$1.00, set against trailing twelve month revenue of US$24.4b and EPS of US$3.26 that frame the latest quarter within a broader run of profitability. Over recent periods, the company has seen quarterly revenue move from US$5.7b in Q2 2025 to US$6.1b in Q2 2026, while basic EPS has shifted from US$0.72 to US$1.00, giving investors a clearer view of how the top and bottom lines are...

Westlake Chemical Partners (WLKP) opened 2026 with Q1 revenue of US$305.7 million and basic EPS of US$0.40, alongside trailing 12 month revenue of about US$1.2 billion and EPS of US$1.64 that reflect 6.7% revenue growth and 10.3% EPS growth over the past year. Over that period, revenue has moved from US$1.09 billion to US$1.23 billion, while EPS has shifted from US$1.49 to US$1.64, giving investors a clearer read on how the current quarter fits into the last year of results. With net margin...

Navitas Semiconductor (NVTS) kicked off Q1 2026 with revenue of US$8.6 million and a basic EPS loss of US$0.15, while over the trailing twelve months it posted revenue of US$40.5 million and a basic EPS loss of US$0.62. Over recent quarters the company has seen revenue move from US$14.0 million and a basic EPS loss of US$0.09 in Q1 2025 to US$7.3 million with a basic EPS loss of US$0.14 in Q4 2025. This frames a story where topline growth expectations and margin pressure are pulling in...

BrightView Holdings (BV) opened Q2 2026 with revenue of US$702.9 million and a basic EPS loss of US$0.08, while trailing 12 month figures show revenue of about US$2.7 billion and a small net loss of US$4.7 million. Over recent quarters, revenue has moved from US$662.5 million in Q2 2025 to US$702.9 million in Q2 2026, with EPS swinging between a loss of US$0.20 in Q1 2025 and a profit of US$0.16 in Q3 2025 before returning to a loss this quarter. This sets up a mixed picture for margins and...

Arista Networks (ANET) has opened 2026 with Q1 revenue of US$2.7 billion and basic EPS of US$0.81, setting the tone for how the rest of the year may unfold. Over recent quarters the company has seen revenue move from US$2.0 billion in Q1 2025 to US$2.7 billion in Q1 2026, while basic EPS has shifted from US$0.65 to US$0.81 across the same period, giving you a clear view of how the top and bottom line are tracking ahead of this latest report. With trailing net profit margins still near the...

Geron (GERN) opened 2026 with Q1 revenue of US$51.8 million, a basic EPS loss of US$0.005, and net income loss of US$3.6 million. This set the tone for another earnings season where growth and profitability stay in focus. Over the last year the company has seen revenue move from US$76.9 million in Q4 2024 to US$196.1 million on a trailing twelve month basis, while the trailing basic EPS loss narrowed from US$0.27 to US$0.10. This leaves investors weighing ongoing losses against improving...

BJ's Restaurants (BJRI) opened 2026 with Q1 revenue of US$358.1 million and basic EPS of US$0.43, alongside trailing 12 month revenue of about US$1.4b and EPS of US$2.05 that reflect reported earnings growth of 98.1% year over year and a 5 year annualized earnings growth rate of 66.7%. Over the last few quarters the company has seen revenue move from US$347.9 million and EPS of US$0.59 in Q1 2025 to US$355.4 million and EPS of US$0.60 in Q4 2025, before landing at the current Q1 2026 levels...

EOG Resources (EOG) opened 2026 with Q1 revenue of US$6.8b and basic EPS of US$3.72, supported by net income of US$1.98b as the stock trades around US$134.69. Over recent periods, total revenue has moved between US$5.4b and US$6.8b a quarter while basic EPS has ranged from about US$1.31 to US$3.72, providing a view of how the earnings line flexes with the top line. Margins are in focus for this release, with investors weighing solid profitability against how efficiently EOG is converting...

PennyMac Mortgage Investment Trust (PMT) opened 2026 with Q1 total revenue of US$82.1 million and basic EPS of US$0.16, setting a quieter tone after a stronger run through 2025. Over the last year, the stock has seen quarterly revenue range from US$145.3 million to US$215.6 million and basic EPS swing between a small loss of US$0.04 and a high of US$0.55, while trailing twelve month EPS reached US$1.16 on revenue of US$758.8 million. Taken together, the latest figures point to a period where...

UroGen Pharma (URGN) opened 2026 with Q1 revenue of US$51.0 million and a basic EPS loss of US$0.47, alongside a net income loss of US$23.6 million, setting a clear marker for how the business is scaling while remaining loss making. The company has seen quarterly revenue move from US$20.3 million in Q1 2025 to US$51.0 million in Q1 2026, while basic EPS over that span ranged from a loss of US$1.05 in Q2 2025 to a loss of US$0.47 in the latest quarter. As a result, investors are getting a...

Q1 2026 results snapshot Recursion Pharmaceuticals (RXRX) has kicked off Q1 2026 with revenue of US$6.5 million, basic EPS of US$0.22 loss, and trailing twelve month revenue of US$66.4 million against a trailing net loss of US$559.8 million. Over recent quarters, the company has seen revenue move between US$4.5 million and US$35.5 million, while quarterly basic EPS has ranged from a loss of US$0.20 to a loss of US$0.53 as the business continues to invest heavily and run at sizable losses,...

Solid Power (SLDP) has released its Q1 2026 numbers, with revenue at US$2.1 million and a basic EPS loss of US$0.06, setting the stage for another quarter where the income statement is firmly in the red. The company has seen quarterly revenue move from US$6.0 million in Q1 2025 to US$2.1 million in Q1 2026, while basic EPS has shifted from a loss of US$0.08 to a loss of US$0.06 over the same period, giving investors a mixed read on the top line and per share performance. With consensus still...

Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE:LOMA) opened 2026 with Q1 results that put revenue at about ARS 218.7b and basic EPS at ARS 351.37, setting a clear marker for how the year is starting to shape up. Over the past few quarters, the company has seen revenue move from about ARS 279.4b in Q4 2024 to ARS 172.9b in Q1 2025 and then to ARS 270.6b in Q4 2025. Basic EPS shifted from ARS 360.89 to ARS 195.07 and then to ARS 64.39, so this latest print lands against a...